J&J to acquire cancer drug developer Ambrx Biopharma for $2 billion

J&J to acquire cancer drug developer Ambrx Biopharma for  billion


An entry sign to the Johnson & Johnson campus shows their logo in Irvine, California on August 28, 2019.

Mark Ralston | AFP | Getty Images

Johnson & Johnson on Monday said it will pay $2 billion in cash to acquire Ambrx Biopharma, a drugmaker specializing in one of the hottest areas of cancer treatment.

Ambrx is aiming to target multiple cancers with drugs called antibody-drug conjugates, or ADCs, which are described by researchers as “guided missiles” to directly target and kill cancer cells and minimize damage to healthy tissue.

The deal, which was announced on the first day of the annual JPMorgan Healthcare Conference, makes J&J the latest drugmaker to bet on ADCs following similar moves by other large drugmakers – including Pfizer, AbbVie and Merck – over the last year. 

The acquisition also comes as J&J scrambles to fill a revenue hole that’s approaching in 2025, when its top-selling drug Stelara, which is used to treat a long-lasting autoimmune disease called psoriasis, is expected to face generic competition. 

“Ambrx’s pipeline and ADC platform present exciting future opportunities to deliver enhanced, precision biologics as we look to transform the treatment of cancer and improve patients’ lives,” Dr. Yusri Elsayed, J&J’s global therapeutic area head of oncology, said in a release.

Under the terms of the deal, J&J will pay $28 a share for Ambrx, or about double the firm’s Friday closing price of $13.63. J&J expects to close the deal in the first half of 2024.

Shares of Ambrx nearly doubled in early trading Monday to just under that purchase price, while J&J’s stock was flat. 



Source

UnitedHealth aims to reassure investors as profits plunge, DOJ investigates its Medicare business
Health

UnitedHealth aims to reassure investors as profits plunge, DOJ investigates its Medicare business

Omar Marques | Lightrocket | Getty Images UnitedHealth Group Chairman and CEO Stephen Hemsley will face the first real test Tuesday of his ability to regain investor confidence as the largest private U.S. insurer reports earnings. The Dow component has seen its share price cut nearly in half since mid-May, with the stock on pace […]

Read More
UnitedHealth says it is cooperating with DOJ investigation into Medicare billing practices
Health

UnitedHealth says it is cooperating with DOJ investigation into Medicare billing practices

The UnitedHealth logo on a laptop arranged in New York, US, on Friday, July 7, 2023. Gabby Jones | Bloomberg | Getty Images UnitedHealth Group revealed Thursday it is facing a Justice Department investigation over its Medicare billing practices, adding to a string of setbacks for a company that owns the nation’s largest and most […]

Read More
Healthy Returns: Researchers move closer to a universal cancer vaccine
Health

Healthy Returns: Researchers move closer to a universal cancer vaccine

Wildpixel | Istock | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. A universal cancer vaccine – what once seemed like a pipe dream – may be inching closer to becoming reality.  On […]

Read More